| 7.3 0.21 (2.96%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.04  |
1-year : | 9.57 |
| Resists | First : | 7.74 |
Second : | 8.19 |
| Pivot price | 7.56 |
|||
| Supports | First : | 7.01 |
Second : | 5.83 |
| MAs | MA(5) : | 7.39 |
MA(20) : | 7.66 |
| MA(100) : | 7.64 |
MA(250) : | 7.82 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.1 |
D(3) : | 28.6 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 11.67 | Low : | 6.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GYRE ] has closed above bottom band by 26.3%. Bollinger Bands are 9.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.38 - 7.41 | 7.41 - 7.44 |
| Low: | 6.95 - 6.99 | 6.99 - 7.02 |
| Close: | 7.24 - 7.3 | 7.3 - 7.36 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Tue, 12 May 2026
Gyre Therapeutics’ F351 NDA Accepted for Priority Review - TipRanks
Tue, 12 May 2026
Gyre Therapeutics announces NMPA acceptance of new drug application for F351 (hydronidone) - marketscreener.com
Tue, 12 May 2026
[8-K] GYRE THERAPEUTICS, INC. Reports Material Event - Stock Titan
Tue, 12 May 2026
China regulator accepts Gyre’s liver fibrosis drug application - Investing.com
Tue, 12 May 2026
New hepatitis B liver drug for China’s tens of millions enters NMPA review - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 81.5 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 1,580 (K) |
| Shares Short P.Month | 1,380 (K) |
| EPS | 0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 4.3 % |
| Operating Margin | 0.3 % |
| Return on Assets (ttm) | 4.9 % |
| Return on Equity (ttm) | 8.2 % |
| Qtrly Rev. Growth | 33.4 % |
| Gross Profit (p.s.) | 1.14 |
| Sales Per Share | 1.2 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | 365 |
| PEG Ratio | 0 |
| Price to Book value | 6.29 |
| Price to Sales | 6.07 |
| Price to Cash Flow | 701.01 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 49.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|